Lung Cancer - KontRASt-06

This study aims to assess the antitumor activity of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS G12C mutation and a PD-L1 expression < 1%, regardless of STK11 mutation status (cohort A), to assess the antitumor activity of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS G12C mutation, a PD-L1 expression ≥1% and an STK11 co-mutation (cohort B), and to assess duration of response (DOR) in both cohorts.

Criteria:

  1. Locally advanced/metastatic NSCLC with no prior systemic treatment for metastatic disease
  2. Mandatory provision of a FFPE tissue sample with ≥20% tumor content for central testing (KRAS, STK11 and PD-L1)
  3. Measurable disease per RECIST 1.1
  4. ECOG ≤1

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, MidState Medical Center

Contacts: Hartford Region: Hayley.Dunnack@hhchealth.org (860) 972-5518, Central Region: Siobhan.Reilly@hhchealth.org, (860) 696-4958

Sponsor(s): Novartis

Cancer Clinical Research Office